Search bioRxiv⌕ Search

Biology subjects

Shikany, C.

Publications and source records attributed to Shikany, C..

2 recordsLinked to original sources

The Synthetic Epitope Atlas: High-Throughput Design and Validation of De Novo Antibody-Antigen Complexes

AO_SCPLOWBSTRACTC_SCPLOWDe novo antibody design models lack sufficient training data to reliably generalize. We demonstrate scalable generation of structural training data for machine learning-driven antibody design by linking in silico designs of antibody-antigen complexes to high-throughput experimental binding validation. Using AlphaSeq, a yeast-based platform for measuring protein binding affinities, we measure the affinity and specificity of thousands of de novo "synthetic epitope proteins" (SEPs) designed to bind to VHHs. The resulting Synthetic Epitope Atlas (SEPIA) pairs over 26 million on- and off-target affinity measurements with computationally designed VHH-SEP "pseudo-structures." We validate strong, specific binding for 1,161 pseudo-structures and >75,000 VHH and SEP mutational variants. We show that these pseudo-structures complement existing structural databases and enable ML models to outperform confidence metrics commonly used to rank de novo antibody designs. Taken together, SEPIA establishes a scalable framework for improving de novo antibody design by augmenting sparse structural data with large-scale experimental binding data.

synthetic biology↗

Massively Multiplexed Affinity Characterization of Therapeutic Antibodies Against SARS-CoV-2 Variants

Antibody therapies represent a valuable tool to reduce COVID-19 deaths and hospitalizations. Multiple antibody candidates have been granted emergency use authorization by the FDA and many more are in clinical trials. Most antibody therapies for COVID-19 are engineered to bind to the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein and disrupt its interaction with ACE2. Notably, several SARS-CoV-2 strains have accrued mutations throughout the RBD that improve ACE2 binding affinity, enhance viral transmission, and escape some existing antibody therapies. Here, we measure the binding affinity of 33 therapeutic antibodies against a large panel of SARS-CoV-2 variants and related strains of clinical significance to determine epitopic residues, determine which mutations result in loss of binding, and predict how future RBD variants may impact antibody efficacy. One-Sentence SummaryBy measuring protein binding in vitro, we identify which clinical antibodies retain binding to various mutant SARS-CoV-2 strains.

bioengineering↗